Husain Yar Khan

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Asfar Sohail Azmi · 14 shared papers, 2020–2026 · strength 2.26
   • Paper KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered? DOI 10.3389/fonc.2022.1013902↗
   • Paper Pharmacological advances in cannabinoid-based therapies for pancreatic cancer: preclinical efficacy of CCL-106 and its … DOI 10.1016/j.esmogo.2025.100211↗
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
2. Amro Aboukameel · 13 shared papers, 2020–2026 · strength 2.00
   • Paper Pharmacological advances in cannabinoid-based therapies for pancreatic cancer: preclinical efficacy of CCL-106 and its … DOI 10.1016/j.esmogo.2025.100211↗
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
3. Sahar F. Bannoura · 11 shared papers, 2022–2026 · strength 1.85
   • Paper KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered? DOI 10.3389/fonc.2022.1013902↗
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
4. Md. Hafiz Uddin · 9 shared papers, 2022–2026 · strength 1.42
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
5. Mohammed Najeeb Al Hallak · 8 shared papers, 2020–2026 · strength 1.23
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
6. Bassel F. El‐Rayes · 6 shared papers, 2022–2026 · strength 0.99
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
7. Ramzi M. Mohammad · 6 shared papers, 2020–2026 · strength 0.91
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
8. Boris Pasche · 5 shared papers, 2023–2026 · strength 0.88
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
9. Philip A. Philip · 6 shared papers, 2020–2025 · strength 0.85
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
   • Paper Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. DOI 10.1016/j.adro.2022.101122↗
10. Muhammad Wasif Saif · 4 shared papers, 2024–2026 · strength 0.72
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
    • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
11. Yiwei Li · 5 shared papers, 2022–2023 · strength 0.71
    • Paper Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. DOI 10.1016/j.adro.2022.101122↗
    • Paper Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model. DOI 10.1002/ctm2.1513↗
    • Paper Connecting the Human Microbiome and Pancreatic Cancer. DOI 10.1007/s10555-022-10022-w↗
12. Eliza Wright Beal · 4 shared papers, 2023–2026 · strength 0.70
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
13. Anthony Frank Shields · 4 shared papers, 2022–2026 · strength 0.64
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
    • Paper Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model. DOI 10.1002/ctm2.1513↗
14. Steve H. Kim · 5 shared papers, 2020–2025 · strength 0.63
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
    • Paper Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model. DOI 10.1002/ctm2.1513↗
    • Paper Molecular profiling of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in cellular and LSL-Kras G12D/+; Trp53… DOI 10.1101/2022.03.08.481108↗
15. Bin Bao · 3 shared papers, 2025–2026 · strength 0.55
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
16. Rachel E. Sexton · 4 shared papers, 2020–2022 · strength 0.50
    • Paper Connecting the Human Microbiome and Pancreatic Cancer. DOI 10.1007/s10555-022-10022-w↗
    • Paper Correction to: Connecting the human microbiome and pancreatic cancer. DOI 10.1007/s10555-022-10037-3↗
    • Paper Molecular profiling of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in cellular and LSL-Kras G12D/+; Trp53… DOI 10.1101/2022.03.08.481108↗
17. P. A. Philip · 2 shared papers, 2025–2026 · strength 0.37
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
18. Azeddine Atfi · 2 shared papers, 2025–2026 · strength 0.37
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
19. R Bonacci · 1 shared paper, 2024 · strength 0.36
    • Paper Editorial: Novel immunological characteristics and immunotherapeutic targets in pancreatic cancer. DOI 10.3389/fimmu.2024.1428740↗
20. Mandana Kamgar · 3 shared papers, 2020–2023 · strength 0.35
    • Paper Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. DOI 10.1016/j.adro.2022.101122↗
    • Paper Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of P… DOI 10.1158/1078-0432.ccr-19-1728↗
    • Paper Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferat… DOI 10.3390/cancers12030750↗
21. Kay‐Uwe Wagner · 2 shared papers, 2023–2024 · strength 0.33
    • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
    • Paper Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor… DOI 10.1101/2023.12.18.572102↗
22. Bayan A. Al-Share · 2 shared papers, 2022 · strength 0.27
    • Paper Connecting the Human Microbiome and Pancreatic Cancer. DOI 10.1007/s10555-022-10022-w↗
    • Paper Correction to: Connecting the human microbiome and pancreatic cancer. DOI 10.1007/s10555-022-10037-3↗
23. K.P. Ray · 1 shared paper, 2025 · strength 0.22
    • Paper Pharmacological advances in cannabinoid-based therapies for pancreatic cancer: preclinical efficacy of CCL-106 and its … DOI 10.1016/j.esmogo.2025.100211↗
24. Anteneh A. Tesfaye · 2 shared papers, 2020 · strength 0.19
    • Paper Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of P… DOI 10.1158/1078-0432.ccr-19-1728↗
    • Paper Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferat… DOI 10.3390/cancers12030750↗
25. William Adrian Hall · 1 shared paper, 2023 · strength 0.17
    • Paper Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. DOI 10.1016/j.adro.2022.101122↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.